FDA Relaxes AAA Panel Meeting Criteria; Thoracic Endograft Approvals Lag
This article was originally published in The Gray Sheet
Executive Summary
Abdominal aortic aneurysm endograft applications will no longer require advisory panel review, unless new issues arise in the course of FDA's premarket evaluation